Back to Home
Free On-DemandOn-Demand Webinar

Breaking the Transfusion Cycle: A New Era of Independence in Lower-Risk Myelodysplastic Syndromes

Release Date

November 18, 2026

Expiration Date

November 19, 2027

Credits

1.0 On-Demand

Topics

Oncology

Program Description

The treatment and management focus for lower-risk myelodysplastic syndromes (LR-MDS) is shifting from symptom management toward disease modification. Recent approvals of non–erythropoiesis-stimulating agents (ESAs) have redefined the standard of care in the frontline and second-line settings, offering disease-modifying potential through durable transfusion independence and improved hemoglobin recovery for patients who have depended on transfusions and ESAs. As these newer therapies redefine the standard of care in LR-MDS, oncology pharmacists need up-to-date education to confidently interpret pivotal trial data and apply cytogenetic and molecular testing results to individualized treatment selection and sequencing decisions. Oncology pharmacists are uniquely positioned to translate this evolving evidence base into safe, effective, and patient-centered care, from choosing between available therapies to managing the dosing, titration, and hematologic toxicities associated with these newer agents. This program will highlight emerging clinical trial data, recommendations for applying patient-specific factors to therapy selection, and best practices for implementing evidence-based dosing and monitoring strategies for patients with LR-MDS.

Target audience: Oncology pharmacists
Type of activity: Application
Release date: November 18, 2026
Expiration date: November 18, 2027
Learner level: Intermediate, Advanced
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

  • Interpret emerging clinical trial data for evidence-based treatment decisions with novel therapies for lower-risk myelodysplastic syndromes (LR-MDS) across frontline and second-line settings
  • Apply patient-specific factors, including transfusion burden, comorbidities, administration preferences, and quality-of-life considerations, to evidence-based therapy selection across the LR-MDS continuum
  • Manage evidence-based strategies for dosing and titration of newer therapies for LR-MDS for safe, effective, and individualized treatment
Breaking the Transfusion Cycle: A New Era of Independence in Lower-Risk Myelodysplastic Syndromes

This activity is supported by an educational grant from Geron.

What's Included
  • Access your activities anytime, anywhere, with a computer, tablet or smartphone
  • Free access with a PTCE account
  • Pharmacy education designed to improve patient care

Follow Us on Social Media!

Related Content

Course

Breaking the Transfusion Cycle: A New Era of Independence in Lower-Risk Myelodysplastic Syndromes

Create Account